Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products

Transfusion

Volumn 49, Issue 9, 2009, Pages 1924-1930

  Unger, Ulrike ^a   Poelsler, Gerhard ^a   Modrof, Jens ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; FIBRIN GLUE; FIBRIN SEALANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BOVINE DIARRHEA VIRUS; CYTOTOXICITY TEST; DRUG MANUFACTURE; DRUG SAFETY; FREEZE DRYING; HEPATITIS A VIRUS; NONHUMAN; PLASMA; PSEUDORABIES HERPETOVIRUS; VIRUS INACTIVATION;

DIARRHEA VIRUS 1, BOVINE VIRAL; FREEZE DRYING; HEPATITIS A VIRUS; HERPESVIRUS 1, SUID; HUMANS; PLASMA; VIRUS INACTIVATION;

EID: 69249194658     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02218.x     Document Type: Article

References (16)

1. Barrett PN, Meyer H, Wachtel I, Eibl J, Dorner F. Inactivation of hepatitis A virus in plasma products by vapor heating. Transfusion 1997 37 : 215 20.
2. Barrett PN, Meyer H, Wachtel I, Eibl J, Dorner F. Determination of the inactivation kinetics of hepatitis A virus in human plasma products using a simple TCID50 assay. J Med Virol 1996 49 : 1 6.
3. Lemon SM, Murphy PC, Smith A, Zou J, Hammon J, Robinson S, Horowitz B. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate. J Med Virol 1994 43 : 44 9.
4. Hart HF, Hart WG, Crossley J, Perrie AM, Wood DJ, John A, McOmish F. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates. Vox Sang 1994 67 : 345 50.
5. Hamman J, Zou J, Horowitz B. Removal and inactivation of Hepatitis A Virus (HAV) during processing of factor VIII concentrates. Vox Sang 1994 67 : 72 7.
6. Roberts PL, Dunkerley C, McAuley A, Winkelman L. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII. Vox Sang 2007 92 : 56 63.
7. Scholz E. Coulometric determination of water. Anal Chem 1983 314 : 567 71.
8. European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). CPMP Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (CPMP/BWP/268/95/rev). 1996.
9. Savage M, Torres J, Franks L, Masecar B, Hotta J. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy. Biologicals 1998 26 : 119 24.
10. Kim IS, Choi YW, Kang Y, Sung HM, Shin JS. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma. J Microbiol Biotechnol 2008 18 : 997 1003.
11. Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, Ciavarella N, Emerson SU, Purcell RH. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994 120 : 1 7.
12. Vermylen J, Peerlinck K. Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang 1994 67 (Suppl 4 8 11.
13. Chudy M, Stahl-Hennig C, Berger A, Nubling CM, Hunsmann G, Rabenau HF, Lower J. Hepatitis A virus infection in tamarins: experimental transmission via contaminated factor VIII concentrates. J Infect Dis 2002 185 : 1170 3.
14. Roberts PL, Hart H. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 2000 28 : 185 8.
15. Prikhod'ko GG, Vasilyeva I, Reyes H, Wong S, Brown KE, Jameson T, Busby TF. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies. Transfusion 2005 45 : 1011 9.
16. Berting A, Modrof J, Unger U, Gessner M, Klotz A, Poelsler G, Kreil TR. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates. Transfusion 2008 48 : 1220 6.